Oligomeric amyloid-β peptide (Aβ) is associated with dysfunctional neuronal networks and neuronal loss in the development of Alzheimer’s disease (AD). Ischemic postconditioning protects against post-ischemic excitotoxicity, oxidative stress, and inflammatory process that have also been implicated in the pathogenesis of AD. Evaluating the roles of ischemic postconditioning in oligomeric Aβ-induced neurotoxicity and underlying signal events may provide potential strategy for medical therapy in AD.
Objectives:
The aim of the present study was to explore whether and how a brief ischemic postconditioning protects against Aβ neurotoxicity in rat hippocampus.
Methods:
Oligomeric Aβ25-35 (20 nmol/rat) or Aβ1-42 (5 nmol/rat) was infused by intracerebroventricular injection in adult male Sprague-Dawley rats. Ischemic postconditioning, a brief episode of global brain ischemia (3 min), was conducted at 1, 3, or 7 days after Aβ treatment, respectively.
Results:
A brief ischemic postconditioning reduced neuronal loss and inhibited the activation of MLK3, MKK3/6, and P38MAPKs in rat hippocampal CA1 and CA3 subfields after Aβ oligomer infusion. An N-methyl-D-aspartate (NMDA) receptor antagonist amantadine, but not non-NMDA receptor antagonist CNQX, reversed the MLK3-MKK3/6-P38MAPK signal events and beneficial effect of ischemic postconditioning on neuronal survival. Such reversion was also realized by NVP-AAM077, a GluN2A-subunit-selective NMDA receptor antagonist. Moreover, posttreatment with low doses of NMDA (5 nmol–40 nmol/rat) suppressed the Aβ-induced P38MAPK signaling and imitated the neuroprotection of ischemic postconditioning against Aβ neurotoxicity.
Conclusions:
Ischemic postconditioning provides neuroprotection against Aβ neurotoxicity by moderate upregulation of NMDA receptor signaling, especially GluN2A-containing NMDA receptor pathway, and thereafter downregulation of MLK3-MKK3/6-P38MAPK signal events.
SantosAN, EwersM, MinthonL, SimmA, SilberRE, BlennowK, PrvulovicD, HanssonO, HampelH (2012) Amyloid-oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer’s disease. J Alzheimers Dis29, 171–176.
4.
AkhterR, SanphuiP, DasH, SahaP, BiswasSC (2015) The regulation of p53 up-regulated modulator of apoptosis by JNK/c-Jun pathway in β-amyloid-induced neuron death. J Neurochem134, 1091–1103.
BurdaJ, DanielisováV, NémethováM, GottliebM, MatiasováM, DomorákováI, MechírováE, FerikováM, SalinasM, BurdaR (2006) Delayed postconditioning initiates additive mechanism necessary for survival of selectively vulnerable neurons after transient ischemia in rat brain. Cell Mol Neurobiol26, 1141–1151.
7.
ZhaoH, SapolskyRM, SteinbergGK (2006) Interrupting reperfusion as a stroke therapy: Ischemic postconditioning reduces infarct size after focal ischemia in rats. J Cereb Blood Flow Metab26, 1114–1121.
8.
RenC, YanZ, WeiD, GaoX, ChenX, ZhaoH (2009) Limb remote ischemic postconditioning protects against focal ischemia in rats. Brain Res1288, 88–94.
9.
LiuJ, XuQ, WangH, WangR, HouXY (2013) Neuroprotection of ischemic postconditioning by downregulating the postsynaptic signaling mediated by kainate receptors. Stroke44, 2031–2035.
10.
Esmaeeli-NadimiA, KennedyD, AllahtavakoliM (2015) Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model. Eur J Pharmacol764, 55–62.
11.
YaoGY, ZhuQ, XiaJ, ChenFJ, HuangM, LiuJ, ZhouTT, WeiJF, CuiGY, ZhengKY, HouXY (2018) Ischemic postconditioning confers cerebroprotection by stabilizing VDACs after brain ischemia. Cell Death Dis9, 1033.
12.
JooSP, XieW, XiongX, XuB, ZhaoH (2013) Ischemic postconditioning protects against focal cerebral ischemia by inhibiting brain inflammation while attenuating peripheral lymphopenia in mice. Neuroscience243, 149–157.
13.
SaadMA, AbdelsalamRM, KenawySA, AttiaAS (2015) Ischemic preconditioning and postconditioning alleviates hippocampal tissue damage through abrogation of apoptosis modulated by oxidative stress and inflammation during transient global cerebral ischemia-reperfusion in rats. Chem Biol Interact232, 21–29.
ZádoriD, VeresG, SzalárdyL, KlivényiP, VécseiL (2018) Alzheimer’s disease: Recent concepts on the relation of mitochondrial disturbances, excitotoxicity, neuroinflammation, and kynurenines. J Alzheimers Dis62, 523–547.
16.
XuY, CaoDH, WuGM, HouXY (2014) Involvement of P38MAPK activation by NMDA receptors and non-NMDA receptors in amyloid-β peptide-induced neuronal loss in rat hippocampal CA1 and CA3 subfields. Neurosci Res85, 51–57.
17.
LiD, AiY (2017) Hydrogen saline suppresses neuronal cell apoptosis and inhibits the p38 mitogen-activated protein kinase-caspase-3 signaling pathway following cerebral ischemia-reperfusion injury. Mol Med Rep16, 5321–5325.
18.
SavageMJ, LinYG, CiallellaJR, FloodDG, ScottRW (2002) Activation of c-Jun N-terminal kinase and p38 in an Alzheimer’s disease model is associated with amyloid deposition. J Neurosci22, 3376–3385.
19.
SunA, LiuM, NguyenXV, BingG (2003) P38 MAP kinase is activated at early stages in Alzheimer’s disease brain. Exp Neurol183, 394–405.
20.
ZhouF, XuY, HouXY (2014) MLK3-MKK3/6-P38MAPK cascades following N-methyl-D-aspartate receptor activation contributes to amyloid-β peptide-induced apoptosis in SH-SY5Y cells. J Neurosci Res92, 808–817.
21.
SchnöderL, HaoW, QinY, LiuS, TomicI, LiuX, FassbenderK, LiuY (2016) Deficiency of neuronal p38α MAPK attenuates amyloid pathology in Alzheimer disease mouse and cell models through facilitating lysosomal degradation of BACE1. J Biol Chem291, 2067–2079.
22.
ChangKW, ZongHF, MaKG, ZhaiWY, YangWN, HuXD, XuJH, ChenXL, JiSF, QianYH (2018) Activation of α7 nicotinic acetylcholine receptor alleviates Aβ1-42-induced neurotoxicity via downregulation of p38 and JNK MAPK signaling pathways. Neurochem Int120, 238–250.
23.
LiS, HongS, ShepardsonNE, WalshDM, ShankaGM, SelkoeD (2009) Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron62, 788–801.
24.
SorianoFX, PapadiaS, HofmannF, HardinghamNR, BadingH, HardinghamGE (2006) Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci26, 4509–4518.
25.
SalehMC, ConnellBJ, SalehTM (2009) Ischemic tolerance following low dose NMDA involves modulation of cellular stress proteins. Brain Res1247, 212–220.
26.
ButterfieldDA, Boyd-KimballD (2004) Amyloid beta-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol14, 426–432.
27.
KupersteinI, BroersenK, BenilovaI, RozenskiJ, JonckheereW, DebulpaepM, VandersteenA, Segers-NoltenI, Van Der WerfK, SubramaniamV, BraekenD, CallewaertG, BarticC, D’HoogeR, MartinsIC, RousseauF, SchymkowitzJ, De StrooperB (2010) Neurotoxicity of Alzheimer’s disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J29, 3408–3420.
28.
JinL, WuWH, LiQY, ZhaoYF, LiYM (2011) Copper inducing Aβ42 rather than Aβ40 nanoscale oligomer formation is the key process for Aβ neurotoxicity. Nanoscale3, 4746–4751.
29.
QianY, YinJ, HongJ, LiG, ZhangB, LiuG, WanQ, ChenL (2016) Neuronal seipin knockout facilitates Aβ-induced neuroinflammation and neurotoxicity via reduction of PPARγ in hippocampus of mouse. J Neuroinflammation13, 145.
GiovanniniMG, ScaliC, ProsperiC, BellucciA, VannucchiMG, RosiS, PepeuG, CasamentiF (2002) Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: Involvement of the38MAPK pathway. Neurobiol Dis11, 257–274.
32.
KimHG, MoonM, ChoiJG, ParkG, KimAJ, HurJ, LeeKT, OhMS (2014) Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. Neurotoxicology40, 23–32.
33.
YuQ, WangY, DuF, YanS, HuG, OrigliaN, RutiglianoG, SunQ, YuH, AingeJ, YanSF, Gunn-MooreF, YanSS (2018) Overexpression of endophilin A1 exacerbates synaptic alterations in a mouse model of Alzheimer’s disease. Nat Commun9, 2968.
34.
MaphisN, JiangS, XuG, Kokiko-CochranON, RoySM, Van EldikLJ, WattersonDM, LambBT, BhaskarK (2016) Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology. Alzheimers Res Ther8, 54.
35.
PierucciF, Garcia-GilM, FratiA, BiniF, MartinesiM, VanniniE, MainardiM, LuzzatiF, PerettoP, CaleoM, MeacciE (2017) Vitamin D3 protects against Aβ peptide cytotoxicity in differentiated human neuroblastoma SH-SY5Y cells: A role for S1P1/p38MAPK/ATF4 axis. Neuropharmacology116, 328–342.
36.
ChangKH, de PabloY, LeeHP, LeeHG, SmithMA, ShahK (2010) Cdk5 is a major regulator of p38 cascade: Relevance to neurotoxicity in Alzheimer’s disease. J Neurochem113, 1221–1229.
37.
MorishimaY, GotohY, ZiegJ, BarrettT, TakanoH, FlavellR, DavisRJ, ShirasakiY and
GreenbergME (2001) Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci21, 7551–7560.
38.
ConcannonCG, GormanAM, SamaliA (2003) On the role of Hsp27 in regulating apoptosis. Apoptosis8, 61–70.
39.
JinY, FanY, YanEZ, LiuZ, ZongZH, QiZM (2006) Effects of sodium ferulate on amyloid-beta-induced MKK3/MKK6-p38 MAPK-Hsp27 signal pathway and apoptosis in rat hippocampus. Acta Pharmacol Sin27, 1309–1316.
40.
HyndMR, ScottHL, DoddPR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int45, 583–595.
41.
DoodyRS, TariotPN, PfeifferE, OlinJT, GrahamSM (2007) Meta-analysis of six-month memantine trials in Alzheimer’s disease. Alzheimers Dement3, 7–17.
42.
SchneiderLS, DagermanKS, HigginsJP, McShaneR (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol68, 991–998.
43.
ZhouX, DingQ, ChenZ, YunH, WangH (2013) Involvement of the GluN2A and GluN2B subunits in synaptic and extrasynaptic N-methyl-D-aspartate receptor function and neuronal excitotoxicity. J Biol Chem288, 24151–24159.
44.
KellermayerB, FerreiraJS, DupuisJ, LevetF, Grillo-BoschD, BardL, Linarès-LoyezJ, BouchetD, ChoquetD,
RusakovDA,
BonP,
SibaritaJB,
CognetL,
SainlosM,
CarvalhoAL,
GrocL (2018) Differential nanoscale topography and functional role of GluN2-NMDA receptor subtypes at glutamatergic synapses. Neuron100, 106–119.
SunY, XuY, ChengX, ChenX, XieY, ZhangL, WangL, HuJ, GaoZ (2018) The differences between GluN2A and GluN2B signaling in the brain. J Neurosci Res96, 1430–1443.
48.
von EngelhardtJ, CosereaI, PawlakV, FuchsEC, KöhrG, SeeburgPH, MonyerH (2007) Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors. Neuropharmacology53, 10–17.
49.
PafundoDE, MiyamaeT, LewisDA, Gonzalez-BurgosG (2018) Presynaptic effects of N-Methyl-D-Aspartate receptors enhance parvalbumin cell-mediated inhibition of pyramidal cells in mouse prefrontal cortex. Biol Psychiatry84, 460–470.
